FDA Approved Products
190 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
VORANIGO
vorasidenib
Growth
R-Pharm US
ORAL · TABLET
2024
SMNDA0/100
VOYDEYA
danicopan
Growth
AstraZeneca
ORAL · TABLET
2024
NDA0/100
VYALEV
foscarbidopa/foslevodopa
Growth
AbbVie
SUBCUTANEOUS · SOLUTION
2024
NDA0/100
WAINUA (AUTOINJECTOR)
eplontersen
Growth
AstraZeneca
SUBCUTANEOUS · SOLUTION
the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
2023
RNANDA0/100
XACDURO (COPACKAGED)
sulbactam and durlobactam
Growth
INTRAVENOUS · POWDER
2023
NDA0/100
XDEMVY
lotilaner ophthalmic solution
Growth
OPHTHALMIC · SOLUTION/DROPS
2023
NDA0/100
XOLREMDI
mavorixafor
Growth
ORAL · CAPSULE
2024
NDA0/100
XPHOZAH
tenapanor
Growth
Ardelyx
ORAL · TABLET
2023
NDA0/100
XROMI
hydroxyurea
Growth
ORAL · SOLUTION
2024
NDA0/100
YCANTH
cantharidin
Growth
Verrica Pharmaceuticals
TOPICAL · SOLUTION
2023
NDA0/100
YORVIPATH
palopegteriparatide
Growth
Ascend Therapeutics
SUBCUTANEOUS · SOLUTION
2024
PeptideNDA0/100
ZEJULA
niraparib
Growth
GSK
ORAL · TABLET
2023
NDA0/100
ZELSUVMI
berdazimer
Growth
TOPICAL · GEL
2024
NDA0/100
ZEPBOUND
tirzepatide
Growth
Eli Lilly and Company
SUBCUTANEOUS · SOLUTION
2023
PeptideNDA0/100
ZEPBOUND (AUTOINJECTOR)
tirzepatide
Growth
Eli Lilly and Company
SUBCUTANEOUS · SOLUTION
2023
PeptideNDA0/100
ZEPBOUND KWIKPEN
tirzepatide
Growth
Eli Lilly and Company
SUBCUTANEOUS · SOLUTION
2023
PeptideNDA0/100
ZILBRYSQ
zilucoplan
Growth
UCB Pharma
SUBCUTANEOUS · SOLUTION
2023
NDA0/100
ZITUVIO
sitagliptin
Growth
ORAL · TABLET
2023
SMNDA0/100
ZORYVE
roflumilast
Growth
Arcutis Biotherapeutics
TOPICAL · FOAM
2023
NDA0/100
ZUNVEYL
benzgalantamine
Growth
AlphaCognition
ORAL · TABLET, DELAYED RELEASE
2024
NDA0/100
ZURNAI (AUTOINJECTOR)
nalmefene hydrochloride
Growth
Purdue Pharma
INTRAMUSCULAR, SUBCUTANEOUS · SOLUTION
2024
NDA0/100
ZURZUVAE
zuranolone
Growth
Biogen
ORAL · CAPSULE
2023
NDA0/100
← PreviousPage 8 of 8